Instituto Linus Pauling Universidad Estatal de Oregon Actualizado en Enero 2015 por: Barbara Delage, Ph.D
Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R
Its weird to say it but I always saved them for my kids
Revenue $598.00M 2024 Valuation $7.00B 2025 Funding $1.00B 2025 Growth Rate (y/y) 66% 2025 Revenue Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% year-over-year from $360M in 2023
They identified gastrointestinal (GI) issues, particularly vomiting and nausea, as the most common side effects for most GLP-1 RAs, while headache and joint pain were most frequently discussed in posts about tirzepatide
Advice on the testing, treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patients medical history